Lyrica Eases Pain From Knee Surgery
Study Shows the Fibromyalgia Drug Also Cuts Pain After Knee Replacement Surgery
Oct. 20, 2008 -- Roughly 300,000 knee replacement surgeries are performed each year in the U.S., and while most patients do well, some have lingering pain even when the operation is successful.
But a strategy developed at Chicago's Rush Medical Center appears to significantly reduce chronic pain following knee surgery.
Rush researchers report that patients treated with the fibromyalgia drug Lyrica immediately before surgery and for two weeks afterward had significantly less chronic pain six months later, compared with patients who were not treated with the drug.
Anesthesiologist and study lead author Asokumar Buvanendran, MD, tells WebMD that it is increasingly clear that drugs given at the time of surgery can have a long-term effect on pain.
"We showed that treating patients immediately before and after surgery was associated with long-term improvements in pain control and quality of life," he says.
Chronic Pain After Surgery
Buvanendran says it is not uncommon for patients to develop chronic pain after surgery, but the condition is poorly understood and underdiagnosed.
Studies suggest that between 1% and 10% of patients who have knee replacement surgery have lingering, long-term pain that is not associated with the arthritis or other conditions that lead to surgery.
Known as chronic neuropathic (nerve-related) pain, the condition has been difficult to treat precisely because there is no widely agreed upon physiological cause.
"Many physicians don't even recognize it and that is why patients often end up going from doctor to doctor to get help," he says.
In June 2007, Pfizer's epilepsy drug Lyrica became the first approved treatment for the chronic pain condition fibromyalgia. It is also approved for the treatment of chronic pain caused by diabetic nerve damage.
According to Pfizer, the drug works by targeting the pain-causing electrical signals in damaged nerves.
With this in mind, the Rush researchers got the idea to treat patients with the drug around the time of surgery in an effort to prevent chronic nerve-related pain later on.
Buvanendran reported the results of the first randomized trial of the strategy Sunday at the 2008 Annual Meeting of the American Society of Anesthesiologists in Orlando, Fla. The study was funded in part by Pfizer.